Pathogenicity, host responses and implications for management of enterohemorrhagic Escherichia coli O157:H7 infection

Canadian Journal of Gastroenterology

Volumn 27, Issue 5, 2013, Pages 281-285

  Ho, Nathan K ^a,b   Henry, Aleah C ^c   Johnson Henry, Kathene ^a   Sherman, Philip M ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Escherichia coli; Host response; Irritable bowel syndrome; Pathogenicity; Treatment

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; FLAGELLIN; GAMMA INTERFERON; JANUS KINASE 1; JANUS KINASE 2; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; SHIGA TOXIN; STAT1 PROTEIN; TOLL LIKE RECEPTOR; VIRULENCE FACTOR;

ABDOMINAL CRAMP; ACUTE KIDNEY FAILURE; AMINO ACID SEQUENCE; ANTIBIOTIC THERAPY; AUSTRALIA; BACTERIAL VIRULENCE; BLOODY DIARRHEA; ENDOPLASMIC RETICULUM; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ENTEROHEMORRHAGIC ESCHERICHIA COLI INFECTION; EPIDEMIC; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI O157; EUROPE; GLOMERULOPATHY; HEMORRHAGIC COLITIS; HOSPITAL INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INTESTINE CELL; IRRITABLE COLON; KIDNEY DYSFUNCTION; NATURAL KILLER T CELL; NONHUMAN; PATHOGENICITY ISLAND; PRIORITY JOURNAL; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84877600300     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2013/138673     Document Type: Review

References (56)

1. Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol 2004; 2: 123-40.
2. Croxen MA, Finlay BB. Molecular mechanisms of Escherichia coli pathogenicity. Nat Rev Microbiol 2010; 8: 26-38.
3. Riley LW, Remis RS, Helgerson SD, et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med 1983; 308: 681-5.
4. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985; 151: 775-82.
5. Levine MM. Escherichia coli that cause diarrhea: Enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. J Infect Dis 1987; 155: 377-89.
6. Bavaro MF. E. coli O157:H7 and other toxigenic strains: The curse of global food distribution. Curr Gastroenterol Rep 2012; 14: 317-23.
7. Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol 2005; 295: 405-18.
8. Maki DG. Don't eat the spinach - controlling foodborne infectious disease. N Engl J Med 2006; 355: 1952-5.
9. Schuster CJ, Ellis AG, Robertson WJ, et al. Infectious disease outbreaks related to drinking water in Canada, 1974-2001. Can J Public Health 2005; 96: 254-8.
10. Melton-Celsa A, Mohawk K, Teel L, O'Brien A. Pathogenesis of Shiga-toxin producing Escherichia coli. Curr Top Microbiol Immunol 2012; 357: 67-103.
11. Ilnyckyj A, Greenberg H, Bernstein CN. Escherichia coli O157:H7 infection mimicking Crohn's disease. Gastroenterology 1997; 112: 995-9.
12. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 2010; 59: 605-11.
13. Ford AC, Thabane M, Collins SM, et al. Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: A cohort study. Gastroenterology 2010; 138: 1727-36.
14. Tornblom H, Holmvall P, Svenungsson B, Lindberg G. Gastrointestinal symptoms after infectious diarrhea: A five-year follow-up in a Swedish cohort of adults. Clin Gastroenterol Hepatol 2007; 5: 461-4.
15. Serna At, Boedeker EC. Pathogenesis and treatment of Shiga toxin-producing Escherichia coli infections. Curr Opin Gastroenterol 2008; 24: 38-47.
16. Andreoli SP, Trachtman H, Acheson DW, Siegler RL, Obrig TG. Hemolytic uremic syndrome: Epidemiology, pathophysiology, and therapy. Pediatr Nephrol 2002; 17: 293-8.
17. Werber D, Krause G, Frank C, et al. Outbreaks of virulent diarrheagenic Escherichia coli - are we in control? BMC Med 2012; 10: 11.
18. Feng P, Lampel KA, Karch H, Whittam TS. Genotypic and phenotypic changes in the emergence of Escherichia coli O157:H7. J Infect Dis 1998; 177: 1750-3.
19. Kyle JL, Cummings CA, Parker CT, et al. Escherichia coli serotype O55:H7 diversity supports parallel acquisition of bacteriophage at Shiga toxin phage insertion sites during evolution of the O157:H7 lineage. J Bacteriol 2012; 194: 1885-96.
20. Laing CR, Buchanan C, Taboada EN, et al. In silico genomic analyses reveal three distinct lineages of Escherichia coli O157:H7, one of which is associated with hyper-virulence. BMC Genomics 2009; 10: 287.
21. Melton-Celsa A, Mohawk K, Teel L, O'Brien A. Pathogenesis of Shiga-toxin producing Escherichia coli. Curr Top Microbiol Immunol 2012; 357: 67-103.
22. Konowalchuk J, Speirs JI, Stavric S. Vero response to a cytotoxin of Escherichia coli. Infect Immun 1977; 18: 775-9.
23. Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983; 1: 619-20.
24. Obrig TG. Escherichia coli Shiga toxin mechanisms of action in renal disease. Toxins (Basel) 2010; 2: 2769-94.
25. Maluykova I, Gutsal O, Laiko M, Kane A, Donowitz M, Kovbasnjuk O. Latrunculin B facilitates Shiga toxin 1 transcellular transcytosis across T84 intestinal epithelial cells. Biochim Biophys Acta 2008; 1782: 370-7.
26. Betz J, Bielaszewska M, Thies A, et al. Shiga toxin glycosphingolipid receptors in microvascular and macrovascular endothelial cells: Differential association with membrane lipid raft microdomains. J Lipid Res 2011; 52: 618-34.
27. Petruzziello-Pellegrini TN, Yuen DA, Page AV, et al. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. J Clin Invest 2012; 122: 759-76.
28. Wong AR, Pearson JS, Bright MD, et al. Enteropathogenic and enterohaemorrhagic Escherichia coli: Even more subversive elements. Mol Microbiol 2011; 80: 1420-38.
29. Tobe T, Beatson SA, Taniguchi H, et al. An extensive repertoire of type III secretion effectors in Escherichia coli O157 and the role of lambdoid phages in their dissemination. Proc Natl Acad Sci U S A 2006; 103: 14941-6.
30. Lim JY, Yoon J, Hovde CJ. A brief overview of Escherichia coli O157:H7 and its plasmid O157. J Microbiol Biotechnol 2010; 20: 5-14.
31. Jones RM, Neish AS. Recognition of bacterial pathogens and mucosal immunity. Cell Microbiol 2011; 13: 670-6.
32. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007; 7: 179-90.
33. Saleh M. The machinery of Nod-like receptors: Refining the paths to immunity and cell death. Immunol Rev 2011; 243: 235-46.
34. Kastenmuller W, Torabi-Parizi P, Subramanian N, Lammermann T, Germain RN. A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread. Cell 2012; 150: 1235-48.
35. Zhang SY, Boisson-Dupuis S, Chapgier A, et al. Inborn errors of interferon (IFN)-mediated immunity in humans: Insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev 2008; 226: 29-40.
36. Shea-Donohue T, Fasano A, Smith A, Zhao A. Enteric pathogens and gut function: Role of cytokines and STATs. Gut Microbes 2010; 1: 316-24.
37. Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and STATs. Immunity 2012; 36: 515-28.
38. Stoiber D, Stockinger S, Steinlein P, Kovarik J, Decker T. Listeria monocytogenes modulates macrophage cytokine responses through STAT serine phosphorylation and the induction of suppressor of cytokine signaling 3. J Immunol 2001; 166: 466-72.
39. Nandan D, Reiner NE. Attenuation of gamma interferon-induced tyrosine phosphorylation in mononuclear phagocytes infected with Leishmania donovani: Selective inhibition of signaling through Janus kinases and Stat1. Infect Immun 1995; 63: 4495-500.
40. Uetani K, Hiroi M, Meguro T, et al. Influenza A virus abrogates IFN-gamma response in respiratory epithelial cells by disruption of the Jak/Stat pathway. Eur J Immunol 2008; 38: 1559-73.
41. Mann BA, Huang JH, Li P, et al. Vaccinia virus blocks Stat1- dependent and Stat1-independent gene expression induced by type I and type II interferons. J Interferon Cytokine Res 2008; 28: 367-80.
42. Ho NK, Ossa JC, Silphaduang U, Johnson R, Johnson-Henry KC, Sherman PM. Enterohemorrhagic Escherichia coli O157:H7 Shiga toxins inhibit interferon-gamma mediated cellular activation. Infect Immun 2012; 80: 2307-15.
43. Fukuda S, Toh H, Hase K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011; 469: 543-7.
44. Mohawk KL, O'Brien AD. Mouse models of Escherichia coli O157:H7 infection and shiga toxin injection. J Biomed Biotechnol;2011: 258185.
45. Crane JK, Byrd IW, Boedeker EC. Virulence inhibition by zinc in shiga-toxigenic Escherichia coli. Infect Immun 2011; 79: 1696-705.
46. Mallick EM, McBee ME, Vanguri VK, et al. A novel murine infection model for Shiga toxin-producing Escherichia coli. J Clin Invest 2012; 122: 4012-24.
47. Allen KJ, Rogan D, Finlay BB, Potter AA, Asper DJ. Vaccination with type III secreted proteins leads to decreased shedding in calves after experimental infection with Escherichia coli O157. Can J Vet Res 2011; 75: 98-105.
48. Goldwater PN, Bettelheim KA. Treatment of enterohemorrhagic Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS). BMC Med 2012; 10: 12.
49. Hickey CA, Beattie TJ, Cowieson J, et al. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med 2011; 165: 884-9.
50. Wong CS, Mooney JC, Brandt JR, et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: A multivariable analysis. Clin Infect Dis 2012; 55: 33-41.
51. Trachtman H, Cnaan A, Christen E, et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: A randomized controlled trial. JAMA 2003; 290: 1337-44.
52. Islam MS, Stimson WH. Production and characterization of monoclonal antibodies with therapeutic potential against Shiga toxin. J Clin Lab Immunol 1990; 33: 11-6.
53. Mukhopadhyay S, Linstedt AD. Manganese blocks intracellular trafficking of Shiga toxin and protects against Shiga toxicosis. Science 2012; 335: 332-5.
54. Sherman PM, Johnson-Henry KC, Yeung HP, Ngo PS, Goulet J, Tompkins TA. Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun 2005; 73: 5183-8.
55. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364: 2561-3.
56. Cai K, Gao X, Li T, Wang Q, et al. Enhanced immunogenicity of a novel Stx2Am-Stx1B fusion protein in a mice model of enterohemorrhagic Escherichia coli O157:H7 infection. Vaccine 2011; 29: 946-52.